Citation

BibTex format

@article{Markiewicz:2026:10.1007/s00259-026-07885-4,
author = {Markiewicz, PJ and Thompson, G and Wardlaw, JM and Wimberley, C and Ritchie, C and Taylor, J-P and Brooks, D and Maxwell, R and Firbank, M and Hoggard, N and Su, L and Wild, J and Hillel, P and Rhodes-Bradford, V and Parkes, LM and O'Brien, JT and Carter, SF and Aigbirhio, FI and Fryer, T and Matthews, PM and Malhotra, P and Grey, G and Hallett, W and Ocal, D and Dickson, JC and De, Vita E and Thomas, DL and Fox, NC and Krokos, G and Mackewn, JE and Marsden, P and Hammers, A and Herholz, K and Barkhof, F and Matthews, JC},
doi = {10.1007/s00259-026-07885-4},
journal = {Eur J Nucl Med Mol Imaging},
pages = {5110--5129},
title = {The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.},
url = {http://dx.doi.org/10.1007/s00259-026-07885-4},
volume = {53},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE: Positron emission tomography combined with magnetic resonance imaging (PET/MR) has not yet achieved the level of adoption of PET/CT. This study aimed to harmonise PET imaging protocols across a national PET/MR network and to quantitatively assess whether PET/MR can achieve reliability comparable to PET/CT. While previous PET test-retest studies have demonstrated good repeatability, they have typically been limited to small cohorts or restricted site configurations. METHODS: We conducted a multi-site harmonisation and rigorous test-retest study across the network of eight PET/MR scanners. Thirty-seven healthy older participants (65-90 years) underwent harmonised one-hour amyloid PET/MR scans using either [[Formula: see text]F]flutemetamol or [[Formula: see text]F]florbetaben on two occasions. Retest scans were performed under conditions of same-site repeatability or multi-site reproducibility. Harmonised acquisition and reconstruction protocols were applied, and amyloid burden was quantified on the Centiloid (CL) scale. RESULTS: CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier. Mean test-retest variability was 2.58%. No statistically significant differences were observed across repeatability versus reproducibility conditions, scanner types, or tracers. CL measurements were highly consistent with three independent blinded visual reads. CONCLUSION: This study demonstrates that harmonised PET/MR achieves high reliability comparable to PET/CT. Although the accuracy of attenuation maps requires checks, this study supports the use of PET/MR for quantitative amyloid imaging in research and therapeutic trials, and provides a valuable open resource of image and raw PET/MR data for further methodological development.
AU  - Markiewicz,PJ
AU  - Thompson,G
AU  - Wardlaw,JM
AU  - Wimberley,C
AU  - Ritchie,C
AU  - Taylor,J-P
AU  - Brooks,D
AU  - Maxwell,R
AU  - Firbank,M
AU  - Hoggard,N
AU  - Su,L
AU  - Wild,J
AU  - Hillel,P
AU  - Rhodes-Bradford,V
AU  - Parkes,LM
AU  - O'Brien,JT
AU  - Carter,SF
AU  - Aigbirhio,FI
AU  - Fryer,T
AU  - Matthews,PM
AU  - Malhotra,P
AU  - Grey,G
AU  - Hallett,W
AU  - Ocal,D
AU  - Dickson,JC
AU  - De,Vita E
AU  - Thomas,DL
AU  - Fox,NC
AU  - Krokos,G
AU  - Mackewn,JE
AU  - Marsden,P
AU  - Hammers,A
AU  - Herholz,K
AU  - Barkhof,F
AU  - Matthews,JC
DO  - 10.1007/s00259-026-07885-4
EP  - 5129
PY  - 2026///
SP  - 5110
TI  - The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.
T2  - Eur J Nucl Med Mol Imaging
UR  - http://dx.doi.org/10.1007/s00259-026-07885-4
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42050257
VL  - 53
ER  -
Download